SLC5A2 and type 2 diabetes mellitus: Therefore, SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, or sotagliflozin) are recommended in the latest guidelines for patients with T2D who have a combination of multiple ASCVD risk factors or who have been diagnosed with ASCVD [24].